联合检测胰岛自身抗体用于低患病率人群1型糖尿病的临床诊断
研究纳入633例新诊断成人糖尿病(≥18岁),按临床表型分为低患病率人群(575例,诊断年龄≥35岁且BMI≥24 kg/m²)和高患病率人群(58例),平行采用放射结合法(RBA)与电化学发光法(ECL)检测胰岛自身抗体(IAbs)。低患病率人群IAbs阳性率低于高患病率人群(16.3% vs 48.3%),且单抗体阳性比例更高(73.4% vs 32.2%)。RBA联合ECL检测有助于在低患病率人群中区分自身免疫性与非自身免疫性糖尿病。
要点
- 低患病率人群IAbs阳性率16.3%,低于高患病率人群的48.3%。
- 低患病率人群单IAbs阳性比例73.4%,高于高患病率人群的32.2%,以谷氨酸脱羧酶抗体最常见。
- 低患病率人群单IAbs阳性不总提示T1D表型,RBA联合ECL检测有助于鉴别自身免疫性糖尿病。
核心结论
- RBA与ECL联合检测自身抗体改善了低患病率人群中自身免疫性与非自身免疫性糖尿病的鉴别。
研究设计与样本
- 共纳入633例新诊断成人糖尿病(≥18岁),按临床表型分为2组:575例诊断年龄≥35岁且BMI≥24 kg/m²者为低患病率人群,其余58例为高患病率人群。
- 所有633例样本平行采用标准放射结合法(RBA)和电化学发光法(ECL)检测胰岛自身抗体(IAbs)。
主要发现
- 低患病率人群检出IAbs阳性94/575(16.3%),高患病率人群28/58(48.3%)。
- 低患病率人群单IAbs阳性69/94(73.4%),高患病率人群9/28(32.2%),以谷氨酸脱羧酶抗体为最常见的单抗体。
- 低患病率人群单IAbs阳性并不总提示T1D表型。
- RBA与ECL联合检测对低BMI、诊断时β细胞功能差且随访中β细胞功能加速下降的低患病率人群具有显著临床价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Single positive islet autoantibodies (IAbs), sometimes detected in healthy individuals and patients with low-risk of developing type 1 diabetes (T1D), are considered to be irrelevant to the development of diabetes, making it difficult to diagnose and classify adult-onset diabetes. OBJECTIVE: To determine the significance and clinical value of IAbs in T1D diagnosis in the low-prevalence population, and to explore whether an electrochemiluminescence IAb detection assay can improve the clinical utility of IAbs in the immunodiagnosis of T1D in the low-prevalence population. METHODS: A total of 633 newly diagnosed patients with adult-onset diabetes (≥18 years old) were divided into 2 groups according to their clinical phenotypes: 575 patients with age at diagnosis ≥35 years and body mass index (BMI) ≥ 24 kg/m2 were considered a low-prevalence population (population with a low prevalence of T1D) and the other 58 patients were considered a high-prevalence population. All the samples from 633 participants were tested with IAbs using standard radiobinding assays (RBAs) and electrochemiluminescence (ECL) assays in parallel. RESULTS: Compared with the high-prevalence population, fewer positive IAbs (94/575, 16.3% vs 28/58, 48.3%) were detected in the low-prevalence population, and more of whom (69/94, 73.4% vs 9/28, 32.2%) were positive for a single IAb, with glutamate decarboxylase antibodies being the most prevalent single IAb. Single-IAb detection in the low-prevalence population did not always suggest the T1D phenotype. Combined detection of IAbs by RBA and ECL assay had a significant clinical utility to distinguish autoimmune diabetes in the low-prevalence population with low BMI, poor β-cell function at the diagnosis, and an accelerated decline in β-cell function during the follow-up. CONCLUSION: Combined autoantibody detection by RBA and ECL assays improved differentiating autoimmune from nonautoimmune diabetes in the low-prevalence population.
引用
- Qi Y, Chen S, Chen H, et al. Combined Detection of Islet Autoantibodies for Clinical Diagnosis of Type 1 Diabetes in the Low-Prevalence Population. J Clin Endocrinol Metab. 2023. PMID: 36480302. doi:10.1210/clinem/dgac720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。